Main renal artery plus branch ablation in treatment of resistant hypertension with renal denervation

Compuscript Ltd

In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2021.0024, Tian-Jiao Lyu, Ling-Yan Li, Xu and colleagues from the Putuo Center Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China discuss main renal artery plus branch ablation in the treatment of resistant hypertension with renal denervation.

The authors of this article studied the safety and efficacy of denervation of renal artery branches in the treatment of resistant hypertension.

Sixty patients with resistant hypertension were enrolled. The patients were randomly assigned to the main renal artery plus branch ablation group or the main renal artery ablation group. The clinical data and operation-related parameters, including number of ablation points, temperature, and average energy, were recorded. Ambulatory blood pressure were taken for all patients at the baseline and at 6 months after treatment. Office blood pressure was recorded before treatment and after treatment every 3 months for 2 years.

Sixty patients with resistant hypertension were enrolled in this study. There were 30 patients in each group. Angiography was performed after ablation. No renal artery complications, such as stenosis and dissection, occurred in the two groups. There was no significant difference in age, sex, BMI, comorbid disease, and medication between the two groups (P > 0.05). The number of ablation points for the main renal artery plus branch ablation group was greater than that for the main renal artery ablation group. The office blood pressure and 24-hour blood pressure were significantly lower 6 months after treatment than before treatment in both groups (P

The authors conclude that main renal artery plus branch ablation is a safe interventional method, but there was no obvious advantage on long-term follow-up compared with only main renal artery ablation.

Citation information: Main Renal Artery Plus Branch Ablation in the Treatment of Resistant Hypertension with Renal Denervation, Tian-Jiao Lyu, Ling-Yan Li, Xu et al., Cardiovasc. Innov. App., 2021, https://doi.org/10.15212/CVIA.2021.0024

Keywords: Renal denervation; resistant hypertension; percutaneous renal artery sympathetic nerve ablation

CVIA is available on the IngentaConnect platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. CVIA is indexed in the EMBASE, ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.